An acute psychotic episode is a severe psychiatric syndrome which might occur in different psychiatric diagnoses. The outcome prediction of relapse rate of a psychotic episode within a certain time frame is difficult and depends on many factors. More and better predictors are required to improve the outcome prediction in order to adjust therapy and follow-up if patients suffer from this acute disease. Copeptin, a surrogate marker for vasopressin, has been proven helpful in the prediction of the outcome in serious somatic diseases. Additionally, a rise of copeptin due to psychological stress was shown. The aim of this study is to investigate the association of the neuroendocrine biomarker copeptin and the prediction of the onset of psychotic episode within one year.
An acute psychotic episode is a severe psychiatric syndrome characterised by symptoms like delusions, hallucinations, and perceptual disturbances. A psychotic episode might occur in different psychiatric diagnoses, such as schizophrenia spectrum disorders and affective disorders (depression and bipolar). The outcome prediction of relapse rate of a psychotic episode within a certain time frame is difficult and depends on many factors. More and better predictors are required to improve the outcome prediction in order to adjust therapy and follow-up if patients suffer from this acute disease. Copeptin, a surrogate marker for vasopressin, has been proven helpful in the prediction of the outcome in serious somatic diseases such as stroke, myocardial infarction, and pneumonia. Additionally, a rise of copeptin due to psychological stress was shown. Some studies have shown an increase in vasopressin levels during acute psychosis, no study has been performed using copeptin. The aim of this study is to investigate the association of the neuroendocrine biomarker copeptin and the prediction of the onset of psychotic episode within one year.
Study Type
OBSERVATIONAL
Enrollment
73
Observation only
University Hospital Basel
Basel, Switzerland
Copeptin level
Association of copeptin at inclusion with relapse rate of a psychotic episode within one year
Time frame: One year
Change in copeptin levels
Change in copeptin levels from day 1 until day 30
Time frame: day 1 until day 30
Recovery of psychotic episode
Time until recovery from the Initial psychotic Episode assessed after 30 days and one year
Time frame: 1 year
Discharge from hospital
Time until discharge from hospital assessed after 30 days and one year
Time frame: one year
Therapy Response assessed by symptom reduction of >30% in PANSS
Therapy Response defined as symptom reduction of \>30% in PANSS assessed after 30 days
Time frame: 30 days
Therapy Response measured by Global Assessment of Functioning (GAF) scale
Therapy Response measured by Global Assessment of Functioning (GAF) scale assessed after 30 days
Time frame: 30 days
Occurence of hyponatremia
Incidence of hyponatremia during an acute psychotic episode assessed at baseline
Time frame: 1 day
Occurence of primary polydipsia
Incidence of primary polydipsia in patients with an acute psychotic episode assessed by reported amount of drinking at baseline
Time frame: 1 day
number of hospital re-admissions
re-admission rate due to a psychotic episode observed over 1 year
Time frame: 1 year
social function after 12 months (functioning) after 12 months assessed by questionnaire
social function after 12 months
Time frame: 1 year
Severity of psychotic symptoms after 12 months compared to baseline assessed by questionnaire
Severity of psychotic symptoms (functioning) after 12 months
Time frame: 1 year
psychological function (functioning) after 12 months compared to baseline assessed by questionnaire
psychological function (functioning) after 12 months
Time frame: 1 year
operational function (functioning) after 12 months compared to baseline assessed by questionnaire
operational function (functioning) after 12 months
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.